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Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus
C Hansen and M Costner Dallas, Texas
Antimalarials have been proven as the mainstay of therapy for cutaneous lupus erythematosus
(CLE) and are effective as first line therapy in at least 50% of patients with discoid lupus
erythematosus (DLE) and up to 80% of those with subacute cutaneous lupus erythematosus
(SCLE). Patients who do not respond to antimalarial therapy present a therapeutic challenge.
Strategies employed in such patients include thalidomide and oral corticosteroids, both of which
are limited by their potentially severe side effects. Other immunosuppressives such as
azathioprine, methotrexate, and cyclosporine have also been utilized but are frequently
ineffective. The recently reported success of mycophenolate mofetil in lupus nephritis has
resulted in increasing use of this agent in patients with systemic lupus erythematosus. We report
our experience with antimalarial-resistant CLE which responded to mycophenolate mofetil. A
total of 24 patients with antimalarial-resistant cutaneous lupus erythematosus who were referred
to our university-based rheumatic skin disease clinic between 2003 and 2005 were treated with
MMF. Patients were given doses which ranged between 2.5 and 3.0 gms/day. Twenty-one
patients had DLE and 3 had SCLE. Twelve of the patients with DLE had a complete response, with
total clearing of skin lesions, while the other 9 DLE patients had a partial response, defined as at
least 50% improvement. All 3 patients with SCLE had a complete response. Side effects were
limited to mild gastrointestinal symptoms. No patient required cessation of therapy secondary to
side effects. Five patients flared with attempted tapering of MMF dose. In conclusion, all
antimalarial-resistant cutaneous lupus patients treated in our practice responded to the addition of
MMF to their treatment regimens, and 15/24 (62.5%) experienced total clearing of their lesions.
Thus, we feel that there is a clear role for the use of MMF in the treatment of cutaneous lupus.
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A single center, open label, pilot study evaluating the safety and effectiveness of
subcutaneous efalizumab in the treatment of oral lichen planus
M Heffernan, D Smith, J Graves and D Bentley Dayton, Ohio and St. Louis, Missouri
Background: Lichen planus (LP) is a papulosquamous inflammatory disorder affecting the skin,
hair, nails and mucous membranes that can be severe and challenging to treat. LP is thought to be
an autoimmune disease in which activated T-cells play an important pathogenic role. Efalizumab
is a humanized monoclonal antibody which targets the CD-11a subunit of leukocyte function-
associated antigen type 1 (LFA-1) and interferes with the activation, trafficking, and cytotoxic
functions of T-cells. Efalizumab is approved for the treatment of moderate to severe plaque
psoriasis. Objective: The purpose of this study was to evaluate the efficacy and safety of
efalizumab in the treatment of oral erosive LP. Methods: This was a single-center, open-label,
pilot study in which subjects with biopsy-proven oral erosive LP received efalizumab as a 1 mg/kg
weekly subcutaneous dose for 12 weeks. The primary efficacy outcome measure was the change
in oral mucosal surface area involvement after 12 weeks of treatment. Secondary outcome
measures included the Clinical Lesion Score (0¼ no lesion; 1¼white striae only; 2¼white striae
and erosiono 1 cm; 3¼white striae and erosion 41 cm; 4¼white striae and ulcerationo 1 cm;
5¼white striae and erosion 41 cm), the 10 cm Visual Analog Scale for pain, and the Oral Health
Impact Profile (OHIP-14) questionnaire. Assessments occurred at baseline and after 1, 4, 8 and 12
weeks on treatment. Safety was evaluated by the type and frequency of adverse events. Platelet
counts were monitored at each study visit. Results: Four patients were enrolled in the study. All
were female and ranged in age form 52–71. Three patients completed the 12 week treatment
course. One patient was withdrawn from the study at week 10 after she developed subacute
cutaneous lupus erythematosus (SCLE). All patients experienced at least a 50% reduction in
affected mucosal surface area, with a mean reduction of 71.1% (range 57.3% to 96.8%). No
patient achieved complete clearance. The mean improvement in Clinical Lesion Score was 1.25
levels. The mean improvement in the 10 cm visual analog pain scale was 84.5%. The mean
improvement in the Oral Health Impact Profile questionnaire was 73.1%. Conclusion: The data
from this small study seems to suggest that efalizumab may have a role in the treatment of oral
erosive lichen planus.
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The development of psoriasis in patients treated with tumor necrosis factor-alpha
inhibitors for rheumatologic conditions: A case series
J Dutz and GC de Gannes Vancouver, British Columbia
The therapeutic approach to rheumatologic conditions has changed dramatically in recent years
with the introduction of biologic therapies such as tumor necrosis factor-alpha (TNF-a) inhibitors.
Targeted therapy with biologic agents has also provided new therapeutic options for patients with
moderate to severe psoriasis. Paradoxically, there have been several reports in the medical
literature of new onset psoriasis or worsening of pre-existing skin disease in patients treated with
TNF-a inhibitors for psoriatic arthritis, rheumatoid arthritis, ankylosing spondilitis, and ulcerative
colitis. The clinical features of characteristic skin lesions occurring with the TNF-a inhibitors were
predominantly a palmoplantar distribution and a pustular pattern. This reaction has been reported
in patients taking each of the three TNF-a inhibitors and seems to be a class effect. The
mechanisms underlying this undesireable effect have yet to be elucidated. However, there is
mounting evidence that a key innate immune pathway for triggering common human
autoimmune disease involves plasmacytoid predendritic cells (PDCs) and intereferon-alpha
(IFN-a) production. It has been shown that PDC-derived IFN-a is essential in stimulating the local
activation and expansion of pathogenic T cells leading to the development of psoriatic skin
lesions. We present a case series with clinical and histopathologic evidence of psoriasis in
patients treated with TNF-a inhibitors for a variety of rheumatologic conditions. We introduce the
hypothesis that the cross-regulation between TNF-a and IFN-a may have a role in the
pathogenesis of this reaction.
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Randomised controlled trial of adjuvant dexamethasone pulse therapy in
pemphigus vulgaris (PEMPULS trial)
MF Jonkman, LF Mentink, MW Mackenzie, GG To´th, M Laseur, FPG Lambert, G Cianchini and
MD Pavlovic´ Groningen, The Netherlands, Rome, Italy, Belgrade, Serbia and Montenegro
Background: There is no evidence for the adjuvant effect of high-dose-corticosteroid pulses in the
treatment of pemphigus vulgaris. Objective: To compare the efficacy of adjuvant dexamethasone
pulse therapy with placebo pulse on top of standard treatment in pemphigus. Design: A
randomised placebo-controlled trial. Setting: International European multi-center, both outpatient
and inpatient study. Patients: A total of 20 patients were included, 11 patients in the
dexamethasone pulse (DP) group and 9 patients in the placebo pulse (PP) group. Interventions:
Randomised double blind treatment: oral dexamethasone 300 mg pulses or placebo pulses 3 days
per month. Open standard treatment: prednisolone 80 mg/day tapered according schedule in
minimal 19 weeks and azathioprine 3 mg/kg/day until end of study. Monthly pulses were
continued until prednisolone was tapered to zero. Follow up was one year. Main outcome
measures: Number of patients in complete remission, the time to and duration of complete
remission, cumulative prednisolone dose, and occurrence of adverse events. Results: Eight of 11
patients treated with DP and all nine with PP reached complete remission during the study. Mean
time to complete remission was 173 days with DP and 176 days with PP. The mean duration of
complete remission within the first year was 151 days for DP and 141 days for PP. Mean
cumulative prednisolone dose was 5300 mg in DP and 4882 mg in PP. A total of 30 adverse
events were recorded in 10 patients in the DP group, versus 14 adverse events in 5 patients in the
PP group. Weight gain (45% of baseline) occurred in 8 patients treated with DP, versus one
patient on PP (Po0.01). No statistically significant differences (P40.05), nor a tendency for an
adjuvant effect of DP on the remission of pemphigus vulgaris was found between the groups.
Conclusion: We were unable to show a benefit of oral dexamethasone pulse therapy as adjuvant
in new patients with pemphigus vulgaris. The addition of pulse therapy to prednisolone induced
more weight gain. The standard regimen of 80 mg prednisolone tapered quickly over a minimal
19 weeks and 3 mg/kg/dd azathioprine was surprisingly effective in reaching complete remission
in the placebo group.
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Multicenter randomized placebo-controlled clinical trial of dapsone as a
glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris
V Werth, D Fivenson, A Pandya, D Chen, M J Rico, J Albrecht, D Jacobus Philadelphia,
Pennsylvania, Detroit, Michigan, Dallas, Texas, Chicago, Illinois, New York, New York and
Princeton, New Jersey
A number of case series have proposed dapsone as a steroid-sparing agent in pemphigus vulgaris.
In the current study, the efficacy of dapsone was assessed in a randomized placebo-controlled
trial. We now report a trial with 19 patients enrolled among 5 centers. Inclusion criteria were
biopsy and direct immunofluorescence-proven pemphigus vulgaris controlled with glucocorti-
coids and/or cytotoxics, disease in maintenance phase, and age 18 to 80 years. Physicians had
tried at least two tapers of glucocorticoids unsuccessfully and had 30 days of stable (o10%
variation) steroid dosage of Z15 mg QD or Z20 mg QOD at enrollment. No pulse steroid
treatment, pulse cytoxan, or plasmapheresis within 2 mos of enrollment was allowed. Patients
unable to taper glucocorticoids by more than 25% within 4 months were declared a failure, and
allowed to switch to the opposite medication while maintaining the double blind. The primary
outcome measure was the ability of patients to taper tor7.5 mg/day within one year of reaching
the maximum dosage of the study drug. Blinded clinical monitors observed the laboratory values.
Of the 9 patients on dapsone, 5 succeeded, 3 failed, and 1 was a drop-out. Of the patients on
placebo, 3 succeeded and 7 failed. This primary endpoint favored the dapsone-treated group, but
was not statistically significant (P¼0.18). 3 patients who failed on placebo crossed over to
dapsone. Of these, all succeeded after crossover to dapsone treatment. We found that overall 8/11
(73%) of patients receiving dapsone vs 3/10 (30%) receiving placebo reached the primary
outcome of a prednisone doser7.5 mg/day. Overall side effects included a drug rash (1 patient),
paresthesias potentially related to dapsone (1), and dyspnea secondary to methemoglobinaemia
(1). There are many challenges to performing such a trial, and these will be discussed. In
conclusion, this trial demonstrates a trend to efficacy of dapsone as a steroid-sparing drug in
maintenance phase pemphigus vulgaris, and defines parameters for planning future PV trials.
6
Rituximab for refractory cutaneous small vessel vasculitis in a patient with a
history of non-hodgkin’s lymphoma
P Eaton, A Funke and J Callen Louisville, Kentucky
A 43-year-old woman with a past medical history of successfully treated large B-cell non-
Hodgkin’s lymphoma (NHL) presented for treatment of a small vessel vasculitis (SVV) of 14
months duration. Prior to her presentation to our clinic the patient had experienced two transient
episodes affecting her legs and feet, a third flare which was temporarily treated with a taper of oral
methylprednisolone, and a fourth flare which was refractory to treatment. During the last flare of
her vasculitis varying dosages of dapsone, oral steroids, colchicine, and hydroxyzine were used.
Upon laboratory evaluation the patient had elevated Epstein-Barr virus antibodies, an elevated
rheumatoid factor, a borderline anti-nuclear antibody titer, elevated c-reactive protein, and a
positive qualitative cryofibrinogen. A CT scan and PET scan revealed mediastinal adenopathy,
and lymph node biopsy showed paracortical hyperplasia, monocytoid B-cell hyperplasia, and an
excess of lambda positive plasma cells. Skin biopsy and direct immunofluorescence were
consistent with leukocytoclastic vasculitis. She was treated with four weekly infusions of
rituximab at 375 mg/m2 with complete resolution of her lesions after the fourth infusion. Her
lesions recurred and were again responsive to a second course of rituximab. Rituximab is
approved for the treatment of relapsed or refractory NHL. Additionally, there have been several
reports of the successful treatment of a variety of vasculitides with rituximab. However, none have
reported the successful treatment of SVV with rituximab in a patient with a history of NHL.
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Oh, Mexico
K Fields Salt Lake City, Utah
This is the case of a 51-year-old Mexican immigrant referred to the dermatology clinic for a one
week history of painful lesions on his left leg, left arm, and right hip. He had a heart transplant two
months prior to presentation for ischemic cardiomyopathy. His medications included tacrolimus,
prednisone, mycophenolate mofetil, sulfamethoxazole-trimethoprim, acyclovir, and nystatin.
Physical examination was significant for indurated red plaques with scale on the left elbow, left
thigh and calf, and right hip. A biopsy from the left calf showed a deep dermal infiltrate with small
intracellular organisms in histiocytes, which stained positively with Giemsa stain. A tissue culture
for AFB, bacterial, and fungal organisms had no growth. Histopathologic slides were sent to the
cdc, and it was suggested that the organisms could represent either Leishmania or Chaga’s
disease. PCR of skin scrapings was positive for Chaga’s disease. A specific serum dipstick test to
differentiate between Chaga’s and Leishmania was positive for Chaga’s and negative for
Leishmania. The patient was diagnosed with Chaga’s disease. Testing of stored serum that had
been drawn prior to the transplant was positive for Chaga’s, making transmission by transplant
unlikely. Evaluation of slides from his explanted heart did not show organisms. This was likely re-
activation of chronic Chaga’s associated with the immunosuppression of his transplant
medications. Interestingly, mycophenolate mofetil is associated with a higher reactivation rate
of Chagas compared to immunosuppressive regimens containing azathioprine. Our patient was
initially treated with itraconazole, with a clinical response of his skin lesions. Blood tests showed
continued parasitemia and he had recurrence of the plaques. He was started on nifurtimox, the
treatment of choice, with improvement. He did not show any evidence, by biopsy or
echocardiography, of Chaga’s involving his transplanted heart. Chagas, which is caused by
trypanosoma cruzi, is probably under-recognized, especially in the United States. 1% of blood
donors in Los Angeles have antibodies to trypanosoma cruzi. Reactivation of Chagas can occur in
transplant recipients, and can be characterized by subcutaneous nodules, also known as
reactivation chagomas, in the absence of heart involvement. With the advent of travel,
immigration, and improving health care, tropical dermatology is no longer seen exclusively in
tropical areas.
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Antibiotic therapy of chronic Henoch-Scho¨nlein purpura
J Hoang and J Callen Louisville, Kentucky
Background. Henoch-Scho¨nlein purpura (HSP) is a small-vessel vasculitis of unknown etiology
thought to be mediated by immunoglobulin A (IgA) immune complexes. There have been
numerous case reports detailing potential triggering infections, medications, and environmental
agents possibly associated with HSP. However, no consistent etiologic agent has been identified.
Observation. A 20-year-old woman presented with a chronic, recurrent purpuric eruption on her
lower extremities, associated with lower extremity edema, arthralgias, headaches, and
gastrointestinal upset. Clinical, histopathologic, and immunofluorescent studies corroborated a
diagnosis of HSP. Extensive laboratory evaluation was unremarkable, except for a consistently
elevated anti-streptolysin-O (ASO) titer. The patient failed several therapeutic interventions,
including systemic corticosteroids and trials of antibiotics (ampicillin and tetracycline). Institution
of an oral cephalosporin resulted in complete remission of her symptoms. Relapse occurred
repeatedly when the antibiotic was discontinued, and remissions were achieved with reinstitution
of therapy. The patient also responded to telithromycin. Conclusion. The etiology of HSP is
uncertain. We present a case of chronic HSP, in association with a persistently elevated ASO titer
that responded dramatically to antibiotic therapy. We will discuss the potential causal
relationship between group A streptococcal infection and HSP in certain patients and the
possible reasoning behind effective treatment with oral antibiotics.
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Henoch-Schonlein purpura in the setting of malignancy
A Garrett Madison, Wisconsin
Henoch-Schonlein purpura (HSP) is a small-vessel vasculitis characterized by perivascular IgA,
C3, and fibrin deposition. It is usually a self-resolving disease of childhood that can involve
almost any organ system, most commonly the skin, GI tract, joints, and kidneys. Palpable
purpura, edema, abdominal pain, and joint pain are frequent presenting symptoms. The cause of
HSP is unknown but common triggers include upper respiratory tract infections and medications.
It affects adults in less than 1/3 of cases but these cases are associated with the most morbidity.
We present a case of HSP in an elderly male, most likely secondary to his newly diagnosed
cholangiocarcinoma of the bile duct. He had a protracted hospital course, which involved acute
on chronic renal failure requiring hemodialysis, ICU admission, migratory thrombophlebitis, and
eventual diagnosis of cholangiocarcinoma. His HSP was picked up late in the course, as the signs
of the disease were obscured during his complex hospitalization. HSP associated with
malignancy is infrequently documented; one case series reported 6 malignancies in 129 HSP
cases. In a review of 19 cases of HSP associated with malignancy, most (63%) of the neoplasms
were solid tumors: lung (6), prostate (2), breast (1), renal (1), stomach (1), and small bowel (1).
Hematologic malignancies (37%) included non-Hodgkin lymphoma (2) Hodgkin disease (2), IgA
multiple myeloma (1), myeloproliferative disease (1), and myelodysplastic syndrome (1). There
has been no prior report of association with carcinoma of the bile duct. This case highlights the
need to be aware of the potential for HSP in adulthood and to keep malignancy in the differential
of potential etiologies.
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Hydroxyurea-induced dermatomyositis, leg ulcers and squamous cell carcinomas
– A challenging clinic problem
S Weinel, J Callen, J Burruss, A Kalajian and J Dixon Louisville, Kentucky
Background: We present the case of a patient with hydroxyurea-induced cutaneous changes
evolving into extensive squamous cell carcinomas involving both of her hands. This ultimately led
to a treatment dilemma whereby the options were to amputate both hands to completely
eliminate the tumor or to simply debulk the areas leaving residual tumor but sparing the hands.
Observation: We present the case of an 83 year old white female with diagnoses of
dermatomyositis sine myositis and chronic myelogenous leukemia who presented with several
large eroded plaques and nodules on the dorsal surfaces of her bilateral hands as well as a similar
lesion on her right upper arm and an ulcer on her ankle. Hand biopsy revealed squamous cell
carcinoma. She had a biopsy done on the hand approximately 4 years earlier which had shown
interface dermatitis consistent with dermatomyositis. In April 2005 she had two areas debulked of
tumor with positive margins and poorly healing wounds. Clearing the margins would have
necessitated amputation of at least her right hand and significant functional damage to her left
hand. She had been on therapy with hydroxyurea as treatment for her CML and it is believed that
this medication may have contributed to her interface dermatitis, malleolar ulceration, and
numerous destructive squamous cell carcinomas. The hydroxyurea was discontinued in
September 2005 and she was started on Anagrelide for treatment of her CML. Currently, the
patient uses imiquimod and retains the function of both of her hands. However, the tumor burden
remains and causes a fair degree of discomfort. Comment: Hydroxyurea is an antimetabolite
commonly used in the treatment of myeloproliferative disorders including chronic myelogenous
leukemia. This agent acts by inhibiting DNA synthesis and repair mechanisms and acts on the skin
by interfering in the replication of the basal layer keratinocytes. Over the past few years, there
have been increasing reports of dermatomyositis-like changes, malleolar ulcers, and extensive
squamous cell carcinomas as a complication of hydroxyurea therapy. This report illustrates a case
where hydroxyurea resulted in cutaneous changes ultimately leading to destructive squamous cell
carcinomas.
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